Comparison Two Point of Care Coagulation Monitoring Systems - the ROTEM Sigma and the Quantra Devic

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-01

Study Completion Date

2019-10-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Human Research Project Risk Category A. In this study no additional intervention or treatment are performed. The whole blood samples are taken from a routinely placed arterial catheter. The blood loss caused by the two additional blood samples is estimated with 2x 2.7ml. The Risk for the patients to participate in this study is minimal.

Clinical observational study of a point of care in vitro diagnostic device, the Quantra®system (Quantra), that received the CE Mark in April 2017 and is approved by the Swiss Medic for clinical use. The Quantra estimates the coagulation strength of whole blood by sonorheometry technology applying a series of ultrasound pulses to a whole blood sample and measuring its stiffness by returning echoes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to investigate to what extent the results of the Quantra corresponds to those of the ROTEM® Sigma (ROTEM). Additionally, the time required for delivery of final results (turnaround time) of all parameters of the Quantra will be examined. Significant differences in the turnaround time between both devices are of high interest as timing is a crucial factor in the diagnosis-based treatment.

Comparison of the coagulation process measurements in turnaround time and results of the ROTEM INTEM CT, HEPTEM CT, EXTEM A10 FIBTEM A10 with corresponding Quantra parameters such as CT, CTH, CTR, CS, PCS, FCS.

The primary aim of the study is to examine whether the two methods of hemostasis analysis are equivalent and how far they correlate.

Secondary aims are to examine the turnaround time of test results in both devices and to examine whether these results would have led to the same therapeutic decisions in a retrospective review of data.

For both devices following data is documented:

* Time for cartridge insertion
* Time first results available
* Time measurement finished

Parameters measured ROTEM Quantra

* INTEM CT Clot Time (CT)
* HEPTEM CT Heparinase Clot time
* (CTH)
* INTEM CT/HEPTEM CT Clot Time Ratio (CTR)
* EXTEM A10 Clot Stiffness (CS)
* FIBTEM A10 Fibrinogen Contribution
* to Clot Stiffness (FCS)
* EXTEM A10 - FIBTEM A10 Platelet Contribution to
* Clot Stiffness (PCS)

Blood loss estimated (mL/6h; mL/12h; mL/24 h) RCP transfused FFP packages transfused Platelet packages transfused Fibrinogen applied F XIII applied

Quantra clot stiffness values are expressed in hectoPascals (hPa), whereas corresponding ROTEM values are expressed as an amplitude in mm. The relationship between amplitude (A in mm) and shear modulus (G in Pascals) is not linear. For a proper comparison the ROTEM amplitude (mm) needs to be converted to Pascals by following formula:

G (Pascals) = (500 x A) / (100 - A),

as described by Solomon C et al, Anaesth Analg 2015; 121:868-78.

The Quantra data that are collected during the study are only observational and will not be used to guide therapeutic interventions

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Inferiority of the Quantra Device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quantra-Device

Point of Care Coagulation Monitoring System

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for cardiac surgery needing a cardiopulmonary bypass
* Age older than18 years
* Written consent of the participation after clarification about the study

Exclusion Criteria

* No consent to participate
* No German comprehension
* Known coagulation disorder

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Werner Baulig

Prof. Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinik Im Park

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Baulig W, Akbas S, Schutt PK, Keul W, Jovic M, Berdat P, von Felten S, Steigmiller K, Ganter MT, Theusinger OM. Comparison of the resonance sonorheometry based Quantra(R) system with rotational thromboelastometry ROTEM(R) sigma in cardiac surgery - a prospective observational study. BMC Anesthesiol. 2021 Oct 28;21(1):260. doi: 10.1186/s12871-021-01469-5.

Reference Type DERIVED

PMID: 34711167 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KlinikHirslande

Identifier Type: -

Identifier Source: org_study_id

NCT04310124